Life sciences company Repligen Corporation (Repligen (RGEN)) is making a big move in cell therapy. On Wednesday, it agreed to acquire BioLife Solutions Inc. (BioLife Solutions (BLFS)) for an enterprise value of roughly $1.5 billion. The deal is all about capitalizing on the booming cell therapy market, where commercial revenues are expected to grow by over 20% annually through 2030.

BioLife is best known for its biopreservation products, especially CryoStor, which keeps cells alive and healthy during storage and transport. That fits neatly with Repligen's existing bioprocessing technologies, which help manufacture cell and gene therapies. Right now, BioLife's products support 18 commercialized therapies and are used in the majority of U.S. cell-based clinical trials. By joining forces, BioLife gets access to Repligen's global sales network, particularly in the fast-growing Asia Pacific region, while Repligen gains a ready-made customer base.

Financial Synergies And Deal Terms

Here's how the math works: BioLife shareholders will receive $11.25 in cash and 0.1442 Repligen shares for each BioLife share they own. That works out to about $31.00 per share, a 24% premium over the 90-day volume-weighted average price as of July 21, 2026. Repligen expects the purchase to immediately boost revenue growth and adjusted margins. The company projects adjusted earnings per share will increase by at least $0.05 in the first year, ramping up to at least $0.25 in the second year. Cost savings are also on the table: at least $20 million initially, growing to at least $30 million the following year.

Repligen's balance sheet looks solid for more deals, too. The company reported $785 million in cash, cash equivalents, and marketable securities as of March 31, 2026, and expects to have over $300 million in cash reserves after the deal closes.

Preliminary Second Quarter Results

Both companies shared preliminary Q2 numbers ahead of the deal. Repligen expects organic revenue growth of 13% and strong margin expansion. BioLife projects a 21% revenue jump to $28.5 million. That's a good sign that both businesses are already on solid footing.

Analysts are on board. William Blair called the acquisition "a great fit" for Repligen, saying it "checks a lot of the key boxes needed for a successful" acquisition. Analyst Matt Larew added that the firm continues to view Repligen as "a best-in-class bioprocessing pure-play" and maintains an Outperform rating on the stock.

Repligen, BioLife Stock Price Activity

In premarket trading on Wednesday, Repligen shares were down 3.10% at $132.75, while BioLife shares jumped 2.77% to $30.00, according to market data.